Sequential administration of dose-dense epirubicin/cyclophosphamide followed by docetaxel/capecitabine for patients with HER2-negative and locally advanced or node-positive breast cancer

Yago Nieto,J. M. Aramendia,Jaime Espinós,Susana De La Cruz,Oscar Fernández-Hidalgo,Marta Santisteban,L. Arbea,Javier Aristu,Rafael Martínez-Monge,M. Moreno,Luis Pina,J. Sola,G. Zornoza,Fernando Martínez Regueira

Sequential administration of dose-dense epirubicin/cyclophosphamide followed by docetaxel/capecitabine for patients with HER2-negative and locally advanced or node-positive breast cancer

2010

Yago Nieto
J. M. Aramendia
Jaime Espinós
Susana De La Cruz
Oscar Fernández-Hidalgo
Marta Santisteban
L. Arbea
Javier Aristu
Rafael Martínez-Monge
M. Moreno
Luis Pina
J. Sola
G. Zornoza
Fernando Martínez Regueira

Purpose Capecitabine is effective against metastatic breast cancer (MBC). We hypothesized that sequential treatment with dose-dense epirubicin/cyclophosphamide (EC) and docetaxel/capecitabine would be active and tolerable in the adjuvant/neoadjuvant setting.

Keywords:

Breast cancer
Capecitabine
Oncology
Cancer
Pharmacology
Breast disease
Epirubicin
Metastatic breast cancer
Cyclophosphamide
Surgery
Internal medicine
Medicine
Docetaxel

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations